|
1) Yasumoto K, Takeo S, Yano T, et al. Role of tumor-infiltrating lymphocytes in the host defense mechanism against lung cancer. J Surg Oncol. 1988; 38: 221-6
|
|
|
|
2) Takenoyama M, Yoshino I, Fujie H, et al. Autologous tumor-specific cytotoxic T lympho-cytes in a patient with lung adenocarcinoma: Implications of the shared antigens expressed in HLA-A24 lung cancer cells. Jpn J Cancer Res. 1998; 89: 60-6
|
|
|
|
|
3) Takenoyama M, Yoshino I, Eifuku R, et al. Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells. Jpn J Cancer Res. 2001; 92: 309-15
|
|
|
|
|
|
4) Sugaya M, Takenoyama M, Osaki T, et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest. 2002; 122: 282-8
|
|
|
|
|
|
5) So T, Takenoyama M, Mizukami M, et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 2005; 65: 5945-52
|
|
|
|
|
|
6) Baba T, Hanagiri T, Ichiki Y, et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci. 2007; 98: 1795-802
|
|
|
|
|
|
7) Takenoyama M, Baurain JF, Yasuda M, et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer. 2006; 118: 1992-7
|
|
|
|
|
|
8) Ichiki Y, Takenoyama M, Mizukami M, et al. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol. 2004; 172: 4844-50
|
|
|
|
|
|
9) Sugaya M, Takenoyama M, Shigematsu Y, et al. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. Int J Cancer. 2007; 120: 1055-62
|
|
|
|
|
|
10) Nagata Y, Hanagiri T, Takenoyama M, et al. Identification of the HLA-Cw＊0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient. Clin Cancer Res. 2005; 11: 5265-72
|
|
|
|
|
|
11) Kuroda K, Takenoyama M, Baba T, et al. Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cyto-toxic T lymphocytes in lung adeno-carcinoma. Cancer Sci. 2009; in press
|
|
|
|
|
|
12) Fukuyama T, Hanagiri T, Takenoyama M, et al. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res. 2006; 66: 4922-8
|
|
|
|
|
|
13) Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005; 23: 6674-81
|
|
|
|
|
|
14) Acres B, Quoix E, Ramlau R, et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J Clin Oncol. 2009; 27: 3027
|
|
|
|
|
|
15) Nemunaitis J, Jahan T, Ross H, et al. Phase 1/2 trial of autologous tumor mixed with an allo-geneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 2006; 13: 555-62
|
|
|
|
|
|
16) Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006; 24: 4721-30
|
|
|
|
|
|
17) Neninger E, Verdecia BG, Crombet T, et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J Immunother. 2009; 32: 92-9
|
|
|
|
|
|
18) Vansteenkiste J, Zielinski M, Linder A, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immuno-therapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol. 2007; 25: 18S: 7554
|
|
|
|
|